Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[surf1944]

7:04AM GlaxoSmithKline, partner of Ligand Pharma (LGND), receives marketing authorization from the European Commission for additional Revolade (Eltrombopag) Indication as the first approved treatment for Chronic Hepatitis C-Associated Thrombocytopenia (GSK) 51.12 : Co announced today that the European Commission has granted an additional indication for Revolade (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon (IFN)-based therapy.1